Artificial Intelligence in Cancer Diagnostics Market Size, Share, Growth, Trends | Report 2022-2030
The global artificial intelligence in cancer diagnostics market was estimated at USD 367.71 million in 2021 and it is expected to surpass around USD 5.3 billion by 2030, poised to grow at a CAGR of 34.51% from 2022 to 2030.
The global artificial intelligence in cancer diagnostics market is expected to witness growth from 2022 to 2030 owing to growing technological advancement in the healthcare sector, growing demand for early detection of cancer, and increasing investment in research in cancer. The demand to improvise the efficiency and efficacy of cancer diagnosis and treatment has led to include new artificial intelligence (AI) technologies. AI allows the integration of a wide variety of streams such as electronic health records, genomics, pathology, radiographic images, and social networks to predict clinical decisions. Within cancer imaging, AI is used to perform 3 major steps detection, classification, and tumor monitoring. The introduction of swarm learning in AI technology allows for predicting cancer through medical images of samples of patient tissues without the need of data from hospitals.
Based on application the market is segmented into screening and diagnosis, tumor identification, and surveillance. Promising application of artificial intelligence, deep learning, machine learning can be used to identify the stage of cancer learning in detecting, characterizing micro movement of cancer, providing appropriate therapeutic options for each individual and predicting patient’s response to immune therapy. Pancreatic and Ovarian cancers are rare but lethal at the same time, as they lack early symptoms that makes their detection difficult. In such cases AI and ML are highly useful to predict detection and therapies. Key players are investing heavily to expand AI technology in cancer diagnosis segments. For instance, in 2022, Whiterabbit.ai signed an agreement with Arterys to expand its AI technology for early detection of cancer. This AI driven partnership is expected to significantly enhance the breast cancer screening volume and compliance.
On the basis of cancer type the market is segmented into Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Others. The growing prevalence of cancer throughout the world is expected to fuel the segment’s growth. As per the statistics provided by WHO, cancer is one of the leading causes of death worldwide. About 10 million deaths were caused due to cancer in 2020. Increasing consumption of alcohol, and tobacco, physical inactivity, unhealthy diet, and rising burden of pollution are some of the major risk factors that increase the burden of cancer cases.
Based on end-users, the market is segregated into hospitals, diagnostic centers, and other. The increasing number of disease-specific diagnostic centers and growing initiatives of the government to expand healthcare structure even in remote areas are expected to fuel the market growth. An increasing number of trained staffs, and professionals are further expected to fuel the market’s growth in the coming future.
On the basis of region, the market has been segmented into North America, Asia Pacific, Europe, Latin America, and MEA. The presence of key players, increasing establishments of start-ups, advancement in the healthcare sectors and presence of favorable regulations are expected to fuel the growth in economically stronger regions. An increasing prevalence of cancer due to the adoption of a sedentary lifestyle is one of the major causes of the market’s growth. For instance, as per the statistics of CDC, in the U.S., annually there will be 2,286,300 cases of cancer by 2050. Owing to these factors, the adoption of AI-based solutions in cancer diagnostics is gaining impetus across the globe.
Strategic initiatives in the form of mergers & acquisitions, product launches, partnerships and collaborations is supporting the market growth. For instance, on July 2022, Roche and EarlySign signed a partnership to develop and commercialize their LungFlag technology. The major focus of their partnership is to make early diagnosis of lung cancer widely available for population.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 367.71 million |
| Revenue Forecast by 2030 | USD 5.3 billion |
| Growth rate from 2022 to 2030 | CAGR of 34.51% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Application, Cancer Type, End-Use, Region |
| Companies Covered |
Roche, EarlySign, IBM, Pfizer, Microsoft, RaySearch Laboratories, Flatiron, cancer center, and others |
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Artificial Intelligence in Cancer Diagnostics Market
5.1. COVID-19 Landscape: Artificial Intelligence in Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Artificial Intelligence in Cancer Diagnostics Market, By Application
8.1. Artificial Intelligence in Cancer Diagnostics Market, by Application, 2022-2030
8.1.1 Screening & Diagnosis
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Tumor Identification
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Surveillance
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Artificial Intelligence in Cancer Diagnostics Market, By Cancer Type
9.1. Artificial Intelligence in Cancer Diagnostics Market, by Cancer Type, 2022-2030
9.1.1. Breast Cancer
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Prostate Cancer
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Lung Cancer
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Colorectal Cancer
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Cervical Cancer
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Artificial Intelligence in Cancer Diagnostics Market, By End-Use
10.1. Artificial Intelligence in Cancer Diagnostics Market, by End-Use, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Diagnostic centers
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Medical Research Institute
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Contract Research Organization
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Artificial Intelligence in Cancer Diagnostics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.1.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
Chapter 12. Company Profiles
12.1. Roche
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. EarlySign
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. IBM
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Microsoft
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. RaySearch Laboratories
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Flatiron
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. cancer center
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. others
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers